Clinical Considerations in Renal Cell Carcinoma: Current Evidence, Guideline Recommendations, and a View to the Future

In this program experts review the recommended guidelines for managing operable advanced or metastatic renal cell carcinoma including the latest data on emerging therapies and adverse event management. Download the slidsesets from a live CME/CE/CPE-certified satellite symposium presented in Chicago at ASCO 2022 and read an expert commentary.

Share

Program Content

Activities

RCC: Adjuvant Approaches and First-Line Therapy for Advanced Disease
Considerations for Selecting Systemic Therapy for Patients with RCC: Adjuvant Approaches and First-Line Therapy for Advanced Disease
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2022

Expires: June 04, 2023

RCC: Second-Line Therapy and Beyond
Optimal Treatment for Patients With Progressive RCC After 1 or More Previous Lines of Therapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2022

Expires: June 04, 2023

RCC: Managing AEs
Optimal Management of Immune-Related Adverse Events for Patients With Advanced RCC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2022

Expires: June 04, 2023

Activities

RCC Treatment Choices
RCC Treatment Choices: How We Are Applying Current Evidence and Guideline Recommendations in Clinical Practice
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 01, 2022

Expires: July 31, 2023

Faculty

cover img faculity

Katy Beckermann, MD, PhD

Assistant Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

cover img faculity

Naomi B. Haas, MD

Professor
Division of Hematology/Oncology
Director
Kidney Cancer and Prostate Cancer Clinical Research Programs
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

cover img faculity

Eric Jonasch, MD

Assistant Professor, Genitourinary Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AVEO Pharmaceuticals, Inc.

Eisai Inc.

Exelixis

Merck Sharp & Dohme Corp.

Pfizer, Inc.